222 related articles for article (PubMed ID: 27692565)
1. HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.
Gao JJ; Tan M; Pohlmann PR; Swain SM
Clin Breast Cancer; 2017 Feb; 17(1):76-78. PubMed ID: 27692565
[TBL] [Abstract][Full Text] [Related]
2. HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.
Pohlmann PR; Graham D; Wu T; Ottaviano Y; Mohebtash M; Kurian S; McNamara D; Lynce F; Warren R; Dilawari A; Rao S; Mainor C; Swanson N; Tan M; Isaacs C; Swain SM
Breast Cancer Res Treat; 2022 Dec; 196(3):571-581. PubMed ID: 36280642
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
5. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
[TBL] [Abstract][Full Text] [Related]
6. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
7. 3-year invasive disease-free survival with chemotherapy de-escalation using an
Pérez-García JM; Cortés J; Ruiz-Borrego M; Colleoni M; Stradella A; Bermejo B; Dalenc F; Escrivá-de-Romaní S; Calvo Martínez L; Ribelles N; Marmé F; Cortés A; Albacar C; Gebhart G; Prat A; Kerrou K; Schmid P; Braga S; Di Cosimo S; Gion M; Antonarelli G; Popa C; Szostak E; Alcalá-López D; Gener P; Rodríguez-Morató J; Mina L; Sampayo-Cordero M; Llombart-Cussac A;
Lancet; 2024 Apr; 403(10437):1649-1659. PubMed ID: 38582092
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
Hassett MJ; Li H; Burstein HJ; Punglia RS
Breast Cancer Res Treat; 2020 May; 181(1):43-51. PubMed ID: 32185586
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.
Spring L; Niemierko A; Haddad S; Yuen M; Comander A; Reynolds K; Shin J; Bahn A; Brachtel E; Specht M; Smith BL; Taghian A; Jimenez R; Peppercorn J; Isakoff SJ; Moy B; Bardia A
Breast Cancer Res Treat; 2018 Dec; 172(3):733-740. PubMed ID: 30220055
[TBL] [Abstract][Full Text] [Related]
12. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
Woodward N; De Boer RH; Redfern A; White M; Young J; Truman M; Beith J
Clin Breast Cancer; 2019 Jun; 19(3):216-224. PubMed ID: 30922805
[TBL] [Abstract][Full Text] [Related]
13. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
[TBL] [Abstract][Full Text] [Related]
14. Effect of pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer: A meta-analysis
.
Tian T; Ye J; Zhou S
Int J Clin Pharmacol Ther; 2017 Sep; 55(9):720-727. PubMed ID: 28737130
[TBL] [Abstract][Full Text] [Related]
15. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
16. Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Bines J; Procter M; Restuccia E; Viale G; Zardavas D; Suter T; Arahmani A; Van Dooren V; Baselga J; Clark E; Eng-Wong J; Gelber RD; Piccart M; Mobus V; de Azambuja E;
Clin Breast Cancer; 2020 Apr; 20(2):174-181.e3. PubMed ID: 31924513
[TBL] [Abstract][Full Text] [Related]
17. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
Tiwari SR; Mishra P; Raska P; Calhoun B; Abraham J; Moore H; Budd GT; Fanning A; Valente S; Stewart R; Grobmyer SR; Montero AJ
Breast Cancer Res Treat; 2016 Jul; 158(1):189-193. PubMed ID: 27324504
[TBL] [Abstract][Full Text] [Related]
19. FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer.
Howie LJ; Scher NS; Amiri-Kordestani L; Zhang L; King-Kallimanis BL; Choudhry Y; Schroeder J; Goldberg KB; Kluetz PG; Ibrahim A; Sridhara R; Blumenthal GM; Pazdur R; Beaver JA
Clin Cancer Res; 2019 May; 25(10):2949-2955. PubMed ID: 30552112
[TBL] [Abstract][Full Text] [Related]
20. Management of patients treated with pertuzumab in the Australian clinical practice setting.
Woodward N; White M; Pugliano L; Tsoi D; Ryan C
Asia Pac J Clin Oncol; 2016 Jun; 12 Suppl 2():5-15. PubMed ID: 27250913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
